McKesson is a Growing Giant

01:02pm, Tuesday, 11'th Jun 2024
McKesson Corporation (MCK) is poised to grow due to an aging population and expanding Type 2 diabetes treatments.
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) announced today that the McKesson board of directors has elected Dr. Deborah Dunsire as a director and member of the Compensation and T
In retirement, stability and downside protection are the main investment objectives. You need retirement-proof stocks that guarantee stable growth with minimal volatility to succeed.
Recently, Zacks.com users have been paying close attention to McKesson (MCK). This makes it worthwhile to examine what the stock has in store.
Investors are optimistic about McKesson's (MCK) strength in its Biologics business.
BOSTON & TORONTO--(BUSINESS WIRE)--Exchange Solutions, a leading provider of personalized loyalty solutions, proudly announces the launch of groundbreaking Generative AI features integrated into its l
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
McKesson's (MCK) fourth-quarter fiscal 2024 results showcase growth in the U.S. Pharmaceutical while lower COVID-related sales hurt the Medical Surgical Solutions segment.
McKesson Corporation (NYSE:MCK ) Q4 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Rachel Rodriguez - VP of Investor Relations Brian Tyler - Chief Executive Officer Britt Vi
The headline numbers for McKesson (MCK) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimate
McKesson Corp reported weaker-than-expected quarterly revenue and profit on Tuesday due to slump in demand for the company's branded and specialty drugs that dragged sales in its U.S. pharmaceutical s
McKesson (MCK) came out with quarterly earnings of $6.18 per share, missing the Zacks Consensus Estimate of $6.34 per share. This compares to earnings of $7.19 per share a year ago.
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) has released its fiscal 2024 fourth quarter financial results. Results can be accessed on McKesson's Investor Relations website at inve
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE